Comparative Pharmacology
Head-to-head clinical analysis: CHIBROXIN versus OFLOXACIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHIBROXIN versus OFLOXACIN.
CHIBROXIN vs OFLOXACIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chibroxin (norfloxacin) is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription.
Inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, preventing DNA replication and transcription.
1-2 drops of 0.3% ophthalmic solution into affected eye(s) every 2 hours while awake for the first 2 days, then every 4 hours for 5-7 days.
400 mg orally or intravenously every 12 hours for 7-14 days; for uncomplicated gonorrhea, 400 mg as a single oral dose.
None Documented
None Documented
Terminal elimination half-life: 6-8 hours in adults with normal renal function. Prolonged to 12-24 hours in moderate renal impairment (CrCl 30-50 mL/min) and >24 hours in severe impairment (CrCl <30 mL/min).
Clinical Note
moderateCiprofloxacin + Digoxin
"Ciprofloxacin may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateOfloxacin + Digoxin
"Ofloxacin may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateLevofloxacin + Digoxin
"Levofloxacin may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateCiprofloxacin + Digitoxin
"Ciprofloxacin may decrease the cardiotoxic activities of Digitoxin."
Terminal elimination half-life is 4-8 hours in adults with normal renal function; prolonged to 20-50 hours in severe renal impairment (CrCl <20 mL/min).
Renal: 98% as unchanged drug; hepatic: 2% as minor metabolites. Biliary/fecal excretion negligible.
Approximately 70-90% of an oral dose is excreted unchanged in urine via glomerular filtration and tubular secretion; about 4-8% is excreted in feces as unchanged drug and metabolites.
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic